OR WAIT null SECS
August 09, 2024
Optimizing AAV vector manufacturing will be necessary to meet anticipated future market demand.
July 26, 2024
Scorpius Holdings expects to launch its first CGMP campaign for mammalian-based biomanufacturing in the 2024 third quarter.
June 18, 2024
Improving the flexibility of cell line development through utilization of platform approaches and suitable partnerships can reduce potential bottlenecks in the development pathway of novel biologics.
June 11, 2024
AGC Biologics has completed an expansion at its Copenhagen, Denmark, site, which doubles its bioreactor capacity for mammalian-based cell culture.
June 07, 2024
FUJIFILM Diosynth Biotechnologies CEO Lars Petersen highlights the company’s strategic goals and meeting market demand for mammalian cell culture capacity.
April 16, 2024
This investment will bolster the company’s large-scale cell culture CDMO business at its planned Fujifilm Diosynth Biotechnologies manufacturing facility in Holly Springs, North Carolina.
February 20, 2024
Challenges in fermentation can be addressed through equipment changes, facility design, and process development.
January 02, 2024
Both adherent and suspension cell culture approaches have their pros and cons, which must be considered for process development.
November 06, 2023
CDMOs are actively exploring and leveraging both new and existing technologies to streamline the cell-line development process at every step.
September 29, 2023
Using a systematic approach and achieving run-to-run consistency are essential.